CV Lattes
ResearcherID
ORCID
Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. Escola Paulista de Medicina (EPM) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Ricardo Sobhie Diaz was born on June 6th, 1962. Physician graduated from Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/UNIFESP) in 1986, with residency at this same Institution in Internal Medicine and Infectious Diseases between 1987 and 1989. Finished master degree in 1991 and doctorate degree in 1993 at EPM/UNIFESP. Worked his post doctoral in laboratory medicine studying the genetic diversity of HIV and its relationship to pathogenesis at the current Former Irwin Memorial Blood Centers in San Francisco, California, USA, by the University of California at Berkeley. He is Associate Professor and Associate Professor of infectious disease discipline at EPM / UNIFESP. He serves as Director of the Retrovirology Laboratory of this Institution, conducting research in virology, molecular biology, transitional (translational) research and clinical research with HIV and related viruses. Leads a group of researchers who conduct research in basic and clinical areas, including graduate students at various levels. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Un tratamiento experimental logró controlar el VIH durante seis meses tras la suspensión del suministro de antirretrovirales |
| A long-sought cure may be closer |
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The project aims to identify metabolic markers of retroviral infection in memory CD4+ T lymphocytes and to develop therapeutic strategies to eliminate these viral sanctuaries. Memory CD4+ T lymphocytes are crucial to ensure a rapid and robust response to pathogens previously encountered by the organism. However, they are also the main reservoirs of the HIV-1 and HTLV-1 retroviruses. Precl…
A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals. Our preliminary data indicate that the use of combined strategies to mitigate the HIV proviral reservoir size among individuals with suppressive antiretroviral treatment achieved unprecedented results in the reduction of HIV DNA present in these cells and in th…
1. Preliminary studies conducted by the team of Prof. Ricardo Sobhie Diaz, point out that combined strategies to (a) overcome residual HIV replication among people undergoing treatment, (b) overcome HIV latency and (c) eliminate HIV in so-called viral sanctuaries, have caused significant clinical impact and unexpected (NCT02961829) .1-19 Thus, initially pilot studies and proof of concept …
AIDS, caused by human immunodeficiency virus (HIV), is a pandemic disease, affecting approximately 37 million people worldwide. Antiretroviral therapy (ART), typically comprising a combination of three drugs, cannot completely eradicate the virus from HIV positive individuals. The elimination of HIV from the body is hampered by the existence of long-lived viral reservoirs, mainly memory T…
This is an interventional proof of concept pilot study to explore the residual HIV replication. Thirty patients under effective HAART for over 2 years will be randomized after recruitment to six different groups and followed by 48 weeks. Group 1. Five patients will receive no further intervention in this group (control group) Group 2. Five patients will receive antiretroviral intensific…
(Only some records are available in English at this moment)
Immunotherapy based on monocyte-derived dendritic cells (MDDCs) is a promising strategy for the treatment of HIV-infected individuals. Due to their remarkable plasticity, heterogeneous populations of MDDCs can be obtained in vitro, depending on the culture conditions. Consequently, the capacity of these cells to secrete cytokines and express molecules that participate in the antigenic pre…
Recent studies have addressed the interactions that occur between the virus and the main host cells in humans (TCD4+ lymphocytes and monocytes), more precisely the interaction between host protein kinases and HIV proteins, during the life cycle of the virus in cells. After the infection is established, the virus promotes a series of changes in the infected cell: the elevation of the level…
This project will contribute to the thematic project multiple interventions to eliminate HIV reservoirs among antiretroviral treated individuals to obtain sustained HIV remission without antiretrovirals support in the areas of bioinformatics and statistics, applying the techniques of these two disciplines to the biological and clinical analyses that derive from the overall project. The fi…
Despite the ability of the antiretroviral therapy at controlling the HIV-1 replication, there are obstacles that prevent the eradication of the infection. The obstacles that prevent the sterilizing cure of HIV-1 infection are the establishment of viral reservoirs that give rise to residual replication and the viral latency. It is known that viral latency is maintained at least in part by …
Highly Active Antiretroviral Therapy (HAART) has been shown great results. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used as first-line therapy. In Brazil, the therapy comprises the first-generation NNRTIs, nevirapine, and efavirenz, and also the second-generation NNRTI, etravirine. These drugs change the HIV-1 reverse transcriptase conformation, an alteration th…
HIV-1 is the main cause of Acquired Immunodeficiency Syndrome (AIDS), characterized by low concentrations of CD4 + T lymphocytes and a high viral replication, leading to the appearance of opportunistic diseases. Most patients are treated with antiretroviral drugs, which act mainly on mechanisms of viral infection in order to reduce cell activation and thereby prevent an increase in viral …
(Only some records are available in English at this moment)
| 2 / 2 | Ongoing research grants |
| 18 / 8 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 32 / 5 | Completed scholarships in Brazil |
| 1 / 0 | Completed scholarships abroad |
| 56 / 18 | All research grants and scholarships |
| Associated processes | |